Please login to the form below

Not currently logged in
Email:
Password:

Teva fights off Novartis to market generic famciclovir tablets

Teva wins favourable ruling against Novartis for a preliminary injunction related to the Israeli firm's famciclovir treatment for genital herpes

Israeli-based Teva has received a favourable ruling from the US District Court for the District of New Jersey regarding a lawsuit filed by Swiss pharmaceutical company Novartis for a preliminary injunction related to Teva's famciclovir, a generic version of Novartis' Famvir treatment for genital herpes.

Teva's ANDA to market famciclovir tablets in 125 mg, 250 mg and 500 mg has already been granted final approval by the FDA.

Famvir had annual sales of approximately USD 200m in the US for the twelve months to 30 June 2007, based on IMS data. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity, which will begin from the date of first commercial marketing.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has yet to be set.

7th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics